Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic ...

Patients with HRR-deficient metastatic castration-resistant prostate cancer experienced a 14-month gain in OS and a 38% lower ...

Pfizer Inc. today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide ...

Investigators report that estradiol works as well as luteinizing hormone–releasing hormone agonists for testosterone suppression and have a much better side-effect profile.

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

as well as patient preferences for side effect profiles when considering whether to use enzalutamide alone, or in combination with ADT. We have many options to right-size treatment for patients in ...

The latest figures on prostate cancer are shocking: it has officially overtaken breast cancer as the most commonly diagnosed ...

"Androgen receptor pathway inhibitors like abiraterone or enzalutamide are initially very effective ... metabolic or endocrinological side effects which are three to seven times higher when compared ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...

Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...